PRNewsWire
13 Sept 2026, 13:20 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Regeneron's Phase 3 Trial of Fianlimab failed to reach statistical significance for its primary endpoint of improvement in progression-free survival (PFS). — The failure of a Phase 3 trial for a key pipeline candidate typically results in significant loss of future revenue potential and valuation.
-0.80A class action lawsuit has been filed against Regeneron alleging executives made false or misleading statements regarding the reliability and success odds of the Fianlimab-Libtayo Study. — Securities litigation creates legal liability, management distraction, and negative sentiment, though it is secondary to the trial failure itself.
-0.40Regeneron altered the Phase III Fianlimab-Libtayo Study to expand the number of patients eligible for analysis of progression-free survival. — Mid-study alterations to analysis parameters can be viewed by investors as a sign of struggle to meet original endpoints.
-0.30Continue reading
5 related stories
Top 1 mover · tap to explore
Which stocks this story touches
The company is facing a class action lawsuit alleging securities fraud following the failure of a Phase III clinical trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
7h ago
